Leptospirosis in Dogs: Clinical Signs, Diagnosis, and One Health Implications

Introduction

Leptospirosis is a globally distributed bacterial zoonosis caused by pathogenic spirochetes of the genus Leptospira. In dogs, infection leads to a spectrum of clinical manifestations ranging from subclinical seroconversion to fulminant acute kidney injury (AKI), hepatopathy, coagulopathy, and pulmonary hemorrhage. The disease is re-emerging in many regions due to urbanization, climate change, and increased exposure to wildlife reservoir hosts [1, 2]. Dogs serve as both incidental hosts and potential sentinels for environmental contamination, making canine leptospirosis a critical component of One Health surveillance [3]. This review provides a detailed examination of the etiologic agents, pathophysiological mechanisms, clinical presentation, diagnostic strategies, and zoonotic implications of leptospirosis in dogs, with emphasis on molecular and serological detection methods.

Etiology and Serovar Epidemiology

The genus Leptospira comprises over 250 antigenically distinct serovars classified into 24 serogroups. Pathogenic species are primarily found in the clade Leptospira interrogans sensu lato, with L. interrogans, L. kirschneri, L. borgpetersenii, L. weilii, and L. noguchii being the most relevant to canine disease [4, 5]. Host adaptation varies by serovar; for example, serovars Canicola and Icterohaemorrhagiae are historically associated with dogs, whereas serovars Grippotyphosa and Pomona are maintained by wildlife such as raccoons, skunks, and rodents [6, 7]. Table 1 summarizes the major serovars implicated in canine leptospirosis and their typical reservoir hosts.

Table 1. Common Leptospira serovars in canine leptospirosis

The distribution of serovars is dynamic and influenced by ecological changes. Urban leptospirosis clusters often involve serovars Icterohaemorrhagiae and Canicola, whereas rural outbreaks may be driven by Grippotyphosa and Pomona [8, 9]. Molecular typing using whole‑genome sequencing and multilocus sequence typing (MLST) has revealed considerable genetic diversity even within serovars, complicating vaccine design [10].

Pathogenesis and Clinical Signs

Mechanism of Infection and Host Interaction

Leptospira enter the canine host through abraded skin or intact mucous membranes after contact with urine‑contaminated water, soil, or fomites [11]. The spirochetes rapidly disseminate via the bloodstream (leptospiremic phase) and colonize the proximal renal tubules, liver, lungs, and ocular tissues. Adhesion to renal epithelial cells is mediated by outer membrane proteins such as LipL32, LipL41, and OmpL1 [12, 13]. The innate immune response involves Toll‑like receptor 2 (TLR2) and TLR4 recognition of leptospiral lipoproteins, triggering a proinflammatory cytokine cascade (IL‑6, TNF‑α, IL‑10) that contributes to tissue damage [14, 15].

Acute Kidney Injury (AKI)

Renal involvement is the hallmark of canine leptospirosis. Leptospiral lipopolysaccharide and hemolysins induce tubular necrosis, interstitial nephritis, and peritubular vasculitis [16]. The resulting AKI manifests as azotemia, isosthenuria, proteinuria, and active urinary sediment (pyuria, granular casts). In severe cases, oliguric or anuric renal failure develops, often requiring renal replacement therapy [17]. The degree of renal injury correlates with the infecting serovar and inoculum dose, as well as host immune status [18].

Hepatopathy and Coagulopathy

Hepatic dysfunction occurs in a subset of dogs, particularly those infected with serovar Icterohaemorrhagiae. Bilirubin accumulation from hepatocellular damage and cholestasis leads to icterus [19]. Coagulopathy results from thrombocytopenia, decreased clotting factor synthesis, and disseminated intravascular coagulation (DIC) [20]. Pulmonary hemorrhage, though less common, carries a poor prognosis and is associated with diffuse alveolar damage and leptospiral invasion of pulmonary endothelium [21].

Other Clinical Syndromes

Chronic carrier dogs may develop asymptomatic persistent renal shedding, a critical source of environmental contamination [22]. Ocular manifestations include uveitis, which is thought to be immune‑mediated and can occur weeks after acute infection [23]. Myalgia, fever, and vomiting are common nonspecific signs.

Diagnosis

Clinical Pathology and Point‑of‑Care Testing

Supportive clinicopathological findings include thrombocytopenia, neutrophilic leukocytosis, elevated serum creatinine and blood urea nitrogen, hyperbilirubinemia, increased hepatic enzyme activities (ALT, ALP), and prolonged coagulation times (PT, aPTT) [24]. Urinalysis typically reveals bilirubinuria, proteinuria, and pyuria. For prognostic assessment, serial monitoring of creatinine and lactate using point‑of‑care analyzers (e.g., automated blood gas and lactate analyzers) can guide fluid therapy and outcome prediction [25]. The article on Point-of-Care Lactate and Blood Gas Analyzers in Canine Emergency Triage provides further context on clinical monitoring in AKI.

Serology: Microscopic Agglutination Test (MAT)

The MAT remains the reference standard for serological diagnosis. Live leptospiral serovars are incubated with serial dilutions of patient serum; agglutination is assessed by darkfield microscopy. A single titer of 1:800 or higher (or a four‑fold rise in paired samples) is considered diagnostic [26]. However, MAT has significant limitations: it requires a panel of geographically relevant serovars, cannot differentiate between acute infection and prior vaccination, and may yield false‑negatives early in infection [27].

Enzyme‑Linked Immunosorbent Assay (ELISA)

ELISA formats targeting IgM or IgG antibodies against conserved antigens (e.g., LipL32) offer higher throughput and earlier detection than MAT [28]. Commercial ELISA kits are available, but cross‑reactivity with vaccinated dogs remains problematic. The principle of antigen detection in ELISA is analogous to that described for Enzyme-Linked Immunosorbent Assay (ELISA) for Feline Leukemia Virus, though the target analytes differ.

Molecular Detection: PCR and Real‑Time PCR

Polymerase chain reaction (PCR) assays targeting the secY, lipL32, or 16S rRNA genes provide sensitive and specific detection of leptospiral DNA in blood, urine, and tissue samples [29, 30]. Real‑time PCR (qPCR) allows quantification of bacterial load and is particularly useful during the leptospiremic phase and for confirming renal shedding. Urine qPCR is the most sensitive sample type after the first week of infection [31]. The article on Canine Giardiasis: Zoonotic Assemblages, Fecal Antigen Testing, and Emerging Treatment Resistance illustrates analogous principles of fecal molecular diagnostics.

Culture and Darkfield Microscopy

Leptospiral culture in Ellinghausen‑McCullough‑Johnson‑Harris (EMJH) medium is definitive but time‑consuming (weeks) and requires specialized laboratory expertise [32]. Darkfield microscopy of urine is rapid but suffers from low sensitivity and specificity due to artifact confusion [33].

Diagnostic Algorithm

Figure 1 presents a diagnostic workflow integrating point‑of‑care, serological, and molecular methods.

Figure 1. Diagnostic algorithm for canine leptospirosis

flowchart TD
    A[Clinical suspicion: fever, vomiting, polyuria/oliguria, icterus], > B{CBC, biochemistry, urinalysis}
    B, > C[Thrombocytopenia, azotemia, bilirubinuria, proteinuria]
    C, > D[Acute phase: blood qPCR + IgM ELISA]
    D, > E{Results}
    E, Positive, > F[Diagnosis confirmed: initiate antibiotics, supportive care]
    E, Negative, > G[Repeat blood qPCR in 48h and collect urine for qPCR]
    G, > H{Urine qPCR}
    H, Positive, > F
    H, Negative, > I[Collect convalescent serum (2-4 weeks) for MAT]
    I, > J{Titer >= 1:800 or four-fold rise}
    J, Positive, > F
    J, Negative, > K[Consider alternative diagnoses]

One Health Implications

Zoonotic Risk to Owners

Leptospirosis is a classic zoonosis. Dogs shed large numbers of spirochetes in urine, posing a direct infection risk to owners, especially children, immunocompromised individuals, and pregnant women [34, 35]. Transmission occurs via contact with urine or contaminated water; indirect aerosolization during cage cleaning can also lead to infection [36]. Outbreaks in veterinary clinics have been documented, underscoring the need for strict infection control protocols [37].

Environmental Contamination and Wildlife Interface

Urine from clinically affected and chronic carrier dogs contaminates soil and surface water, perpetuating the environmental reservoir. Peri‑urban wildlife (rodents, raccoons, opossums) amplify the pathogen and serve as bridge hosts between domestic and sylvatic cycles [38]. The article on Tick-Borne Parasites in White-Tailed Deer: Babesia and Theileria Prevalence, PCR-Based Surveillance, and Impact on Livestock Interface illustrates similar cross‑species surveillance principles.

One Health Surveillance and Vaccination

Vaccination of dogs with bacterin‑based vaccines containing the most prevalent serovars (e.g., Canicola, Icterohaemorrhagiae, Grippotyphosa, Pomona) reduces clinical disease and shedding [39]. However, vaccines do not prevent infection by non‑vaccinal serovars, and immunity wanes over months, necessitating booster protocols [40]. Monitoring seroreactivity in dog populations can serve as an early warning system for environmental leptospirosis risk [41]. The article on Antimicrobial Resistance in Livestock-Associated Staphylococcus aureus: Genomic Epidemiology and One Health Implications similarly discusses the interconnectedness of human, animal, and environmental health.

Diagnostic Stewardship and Public Health Reporting

Veterinarians should report confirmed canine leptospirosis cases to public health authorities to facilitate outbreak investigations and risk communication [42]. The choice of diagnostic assay influences case confirmation; molecular methods (qPCR) are preferred for early detection, while MAT remains essential for serovar surveillance [43]. Laboratories must adhere to biosafety level 2 practices when handling potentially infected specimens.

Prevention and Control

Vaccination Protocols

Dogs at risk (hunting dogs, those in kennels or rural areas) should receive the quadrivalent vaccine annually or semi‑annually in high‑pressure regions [44]. Adverse reactions, including anaphylaxis, are more common with bacterin vaccines than with recombinant or subunit candidates currently under development [45].

Environmental Biosecurity

Reducing rodent populations, preventing access to stagnant water, and disinfecting kennel surfaces with bleach or quaternary ammonium compounds decrease environmental contamination [46]. Owners should wear gloves when cleaning urine and avoid letting dogs swim in suspect freshwater habitats.

Antimicrobial Therapy

Doxycycline (5 mg/kg PO q12h or 10 mg/kg PO q24h for 2 weeks) is the drug of choice for eliminating the leptospiremic and renal carrier phases [47]. Penicillin derivatives (e.g., ampicillin) are effective for acute systemic infection but do not clear renal carriage [48]. Supportive care includes intravenous fluids, antiemetics, and, in severe AKI, hemodialysis or peritoneal dialysis.

Conclusions

Canine leptospirosis remains a diagnostic and therapeutic challenge owing to its variable presentation, serovar diversity, and zoonotic potential. Advanced molecular techniques such as qPCR have improved early detection, but the MAT continues to underpin serological surveillance. A One Health approach integrating veterinary diagnostics, wildlife ecology, and public health surveillance is essential to mitigate the impact of this re‑emerging zoonosis.

References

[1] Levett PN. Leptospirosis. Clin Microbiol Rev. 2001;14(2):296‑326.

[2] Sykes JE, Hartmann K, Lunn KF, et al. 2010 ACVIM small animal consensus statement on leptospirosis: diagnosis, epidemiology, treatment, and prevention. J Vet Intern Med. 2011;25(1):1‑13.

[3] Ellis WA. Animal leptospirosis. Curr Top Microbiol Immunol. 2015;387:99‑137.

[4] Fouts DE, Matthias MA, Adhikarla H, et al. What makes a bacterial species pathogenic?: comparative genomic analysis of the genus Leptospira. PLoS Negl Trop Dis. 2016;10(2):e0004403.

[5] Picardeau M. Diagnosis and epidemiology of leptospirosis. Med Mal Infect. 2013;43(1):1‑9.

[6] Alston JM, Broom JC. Leptospirosis in Man and Animals. Edinburgh: E&S Livingstone; 1958.

[7] Ward MP, Guptill LF, Wu CC. Evaluation of environmental risk factors for leptospirosis in dogs: 1997‑2003. J Am Vet Med Assoc. 2004;225(1):72‑77.

[8] Gautam R, Guptill LF, Wu CC, et al. Spatial and temporal patterns of leptospirosis in dogs in the United States. J Am Vet Med Assoc. 2010;237(6):670‑678.

[9] Benacer D, Thong KL, Verasahib KB, et al. Human leptospirosis in Malaysia: a review. Asian Pac J Trop Biomed. 2016;6(2):126‑131.

[10] Galloway RL, Levett PN. Application and validation of PFGE for serovar identification of Leptospira clinical isolates. J Clin Microbiol. 2010;48(10):3625‑3630.

[11] Faine S, Adler B, Bolin C, et al. Leptospira and Leptospirosis. 2nd ed. Melbourne: MediSci; 1999.

[12] Haake DA, Chao G, Zuerner RL, et al. The leptospiral major outer membrane protein LipL32 is a lipoprotein expressed during mammalian infection. Infect Immun. 2000;68(4):2276‑2285.

[13] Cullen PA, Haake DA, Adler B. Outer membrane proteins of pathogenic spirochetes. FEMS Microbiol Rev. 2004;28(3):291‑318.

[14] Werts C, Tapping RI, Mathison JC, et al. Leptospiral lipopolysaccharide activates cells through a TLR2‑dependent mechanism. Nat Immunol. 2001;2(4):346‑352.

[15] Viriyakosol S, Matthias MA, Swancutt MA, et al. Toll‑like receptor 4 protects against lethal Leptospira interrogans serovar Icterohaemorrhagiae infection and correlates with expression of IL‑12. Infect Immun. 2006;74(9):5158‑5165.

[16] Yang CW, Wu MS, Pan MJ. Leptospirosis renal disease. Nephrol Dial Transplant. 2001;16(Suppl 5):73‑77.

[17] Stokes JE, Forrester SD. Acute kidney injury in dogs: a review. J Vet Emerg Crit Care. 2013;23(6):603‑621.

[18] Miller RI, Ross JP, Miller SC, et al. Naturally occurring leptospirosis in dogs: clinical and pathologic findings. J Vet Intern Med. 1992;6(3):158‑165.

[19] Adin CA, Cowgill LD. Treatment and outcome of dogs with leptospirosis: 36 cases (1990‑1998). J Am Vet Med Assoc. 2000;216(3):371‑375.

[20] Brown CA, Roberts AW, Miller MA, et al. Leptospira interrogans serovar Grippotyphosa infection in dogs. J Am Vet Med Assoc. 1996;209(7):1265‑1267.

[21] Nally JE, Chantranuwat C, Wu XY, et al. Alveolar septal deposition of immunoglobulin and complement parallels pulmonary hemorrhage in a guinea pig model of severe pulmonary leptospirosis. Am J Pathol. 2004;164(3):1115‑1127.

[22] Harkin KR, Roshto YM, Sullivan JT, et al. Clinical and serologic evaluation of leptospirosis in dogs: 145 cases (1994‑1998). J Am Vet Med Assoc. 2000;216(3):376‑381.

[23] Verma A, Stevenson B, Adler B. Leptospiral uveitis – there is more to it than meets the eye!. Vet Microbiol. 2012;158(3‑4):236‑244.

[24] Rentko VT, Clark N, Ross LA, et al. Canine leptospirosis: a retrospective study of 17 cases. J Vet Intern Med. 1992;6(4):235‑244.

[25] Silverstein DC, Drobatz KJ. Clinical evaluation of the critically ill dog. Vet Clin North Am Small Anim Pract. 2006;36(5):1039‑1059.

[26] World Health Organization. Human leptospirosis: guidance for diagnosis, surveillance and control. WHO; 2003.

[27] Smith CR, Ketterer PJ, McGowan MR, et al. A review of laboratory diagnosis of leptospirosis. Aust Vet J. 1994;71(11):349‑353.

[28] Hartleben CP, Ko AI, McBride AJ, et al. Evaluation of recombinant LipL32 and LipL41 for serodiagnosis of leptospirosis. Mem Inst Oswaldo Cruz. 2003;98(7):927‑932.

[29] Merien F, Amouriaux P, Perolat P, et al. Polymerase chain reaction for detection of Leptospira spp. in clinical samples. J Clin Microbiol. 1992;30(9):2219‑2224.

[30] Smythe LD, Smith IL, Smith GA, et al. A quantitative PCR (TaqMan) assay for pathogenic Leptospira spp. BMC Infect Dis. 2002;2:13.

[31] Rojas P, Monahan AM, Schuller S, et al. Detection and quantification of leptospires in urine of dogs: a maintenance host for the zoonotic disease? Vet Microbiol. 2010;143(2‑4):335‑339.

[32] Faine S. Guidelines for the control of leptospirosis. WHO Offset Publ. 1982;67:1‑171.

[33] Turner LH. Leptospirosis. BMJ. 1967;2(5544):98‑103.

[34] Greene CE, Sykes JE. Leptospirosis in dogs. In: Greene CE, ed. Infectious Diseases of the Dog and Cat. 4th ed. St. Louis: Elsevier; 2012:431‑447.

[35] Jansen A, Luge E, Guerra B, et al. Leptospirosis in urban wild boars, Berlin, Germany. Emerg Infect Dis. 2007;13(5):739‑742.

[36] Campagnolo ER, Warwick MC, Marx HL Jr, et al. Analysis of the 1998 outbreak of leptospirosis in Missouri in humans exposed to infected swine. J Am Vet Med Assoc. 2000;216(5):676‑682.

[37] Baverud V, Gunnarsson A, Englund S, et al. Leptospira seroprevalence in dogs in Sweden. Acta Vet Scand. 2009;51:26.

[38] Desvars A, Michault A, Bourhy P. Leptospirosis in the western Indian Ocean islands: what is known so far? Acta Trop. 2013;125(2):135‑144.

[39] Andre‑Fontaine G, Branger C, Gray AW, et al. Comparison of the efficacy of three commercial bacterins against leptospirosis in dogs. J Vet Intern Med. 2003;17(3):389‑395.

[40] Klaasen HL, Van der Veen M, Sutton D, et al. A placebo‑controlled study to evaluate the efficacy of a multivalent canine leptospirosis vaccine against challenge with Leptospira interrogans serovar Pomona and Leptospira borgpetersenii serovar Sejroe. Vet Ther. 2008;9(4):281‑293.

[41] Ward MP, Guptill LF, Prahl A, et al. Serovar‑specific prevalence and risk factors for leptospirosis in dogs. J Am Vet Med Assoc. 2004;224(12):1958‑1963.

[42] Levett PN, Haake DA. Leptospira species (leptospirosis). In: Long SS, Prober CG, Fischer M, eds. Principles and Practice of Pediatric Infectious Diseases. 5th ed. Philadelphia: Elsevier; 2017:856‑860.

[43] Musso D, La Scola B. Laboratory diagnosis of leptospirosis: a challenge. J Microbiol Immunol Infect. 2013;46(4):245‑252.

[44] Moore GE, Guptill LF, Ward MP, et al. Adverse events diagnosed within three days of vaccine administration in dogs. J Am Vet Med Assoc. 2005;227(7):1102‑1108.

[45] Palaniappan RU, Chang YF, Justif S, et al. Cloning and molecular characterization of an immunogenic LigA protein of Leptospira interrogans. Infect Immun. 2002;70(11):5924‑5930.

[46] Bolin CA. Leptospirosis. In: Aiello SE, ed. The Merck Veterinary Manual. 10th ed. Whitehouse Station: Merck; 2010:658‑662.

[47] Hoskins JD, DVM. Leptospirosis in dogs. Compend Contin Educ Pract Vet. 2008;30(2):94‑104.

[48] Alt DP, Zuerner RL, Bolin CA. Evaluation of antibiotics for treatment of cattle infected with Leptospira borgpetersenii serovar Hardjo. J Am Vet Med Assoc. 2001;219(5):636‑639.

[49] Koizumi N, Watanabe H. Leptospirosis: a re‑emerging zoonosis. Uirusu. 2007;57(